Which generation of targeted drug is Bosutinib?

Bosutinib is a second generation TKI, Bosutinib, trade name: Bosulif , is a small molecule BCR-ABL and src tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia (CML). Bosutinib is both a substrate and an inhibitor of p-glycoprotein (P-gp) and CYP3A4. Therefore, P-gp and CYP3A4 inhibitors may increase bosutinib plasma levels. Likewise, CYP3A4 inducers may decrease bosutinib plasma concentrations. It may also alter the metabolism and uptake of other drugs that are substrates of P-gp and CYP3A4 (into the GIT via their P-gp inhibition).

Based on findings from animal studies and its mechanism of action, it may cause fetal harm when administered to pregnant women. If used during pregnancy or if the patient becomes pregnant while receiving the drug, inform the patient of the potential fetal risk. It is unknown whether bosutinib or its metabolites distribute into breast milk, affect breastfed children, or affect milk production,It was detected in the milk of lactating rats. Avoid breastfeeding during treatment and for ≥2 weeks after the last dose. Verify pregnancy status in females of reproductive potential before initiating bosutinib therapy. Advise females of reproductive potential to use effective contraception during treatment with bosutinib and for ≥2 weeks after the last dose. Safety and effectiveness for pediatric usehave not been established. If you want to get more high-quality information, you can contact Yaode, and Yaode will do its best to learn more about high-quality overseas drugs for you.